AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Whether they’re suffering from red, itchy eyes during allergy season, dealing with the discomfort of ear wax buildup or ...

Introduction: The global botulinum toxin market has evolved from being a beauty-industry phenomenon to becoming a ...

$1.5 million is the 'magic number' for retirement savings—here's how long it lasts in every U.S. state ...

CollPlant Biotechnologies , a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), ...

The growth in the historical period was largely attributed to the increasing prevalence of pelvic cancers, the aging population, the rise in cervical cancer cases, government initiatives, and ...

The c-MET CDx for NSCLC assay is intended to detect individuals who may benefit from targeted therapies such as AbbVie’s ...

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical ...

AbbVie in partnership with the University of Toronto's SpinUp, are pleased to announce Neuropeutics Inc as the recipient of the AbbVie Biotech Innovators Award, a national prize to help foster ...

ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...